GW Pharmaceuticals Plc

(GWPH) Trade

By |

Profile

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. Its business activities are functioned through three reportable segments which are Commercial, Sativex Research and Development and Pipeline Research and Development. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

Contact Information

Website: www.gwpharm.com
Email: publicrelations@gwpharm.com
Main Phone: +44 1223266800
Address: Sovereign House, Chivers Way
Address 2: Vision Park, Histon
City / Town: Cambridge
Country: GBR
Postal Code: CB24 9BZ

Issuer Information

Exchange: NSD
CEO: Justin David Gover
Employees: 791

Equities News

View More

Profile

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. Its business activities are functioned through three reportable segments which are Commercial, Sativex Research and Development and Pipeline Research and Development. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

Contact Information

Website: www.gwpharm.com
Email: publicrelations@gwpharm.com
Main Phone: +44 1223266800
Address: Sovereign House, Chivers Way
Address 2: Vision Park, Histon
City / Town: Cambridge
Country: GBR
Postal Code: CB24 9BZ

Issuer Information

Exchange: NSD
CEO: Justin David Gover
Employees: 791

Equities News

View More
$ 96.10 $ -4.95 (-4.90%)
Last Price 96.10 Change $ -4.95 Change % -4.90 Tick N/A
Bid 96.00 Bid Size 100.00 Ask 96.88 Ask Size 100.00
Open 100.50 High 101.75 Low 95.98 Prev Close 101.05
Last Trade Volume 1 mi 52 Wk Hi 196.00 52 Wk Low 90.14
Market Cap 3 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 30,913,177.00 EPS (TTM) -9.38 PE Ratio N/A Exchange NSD
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 205 205 205 205
Low Target Price Estimate 61 61 61 61
Mean Target Price Estimate 151.2 151.2 151.2 151.2
Standard Deviation 53.83 53.83 53.83 53.83
Date of Most Recent Estimate 06/01/18 05/22/18 05/22/18 06/01/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 1 1
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2 2 1.93 1.93